785 related articles for article (PubMed ID: 20306243)
1. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
5. Targeting epigenetic changes in acute myeloid leukemia.
Blum W; Marcucci G
Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
7. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic gene regulation in cancer.
Ballestar E; Esteller M
Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
[TBL] [Abstract][Full Text] [Related]
9. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation as a pathogenic event and as a therapeutic target in AML.
Schoofs T; Müller-Tidow C
Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874
[TBL] [Abstract][Full Text] [Related]
11. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
12. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
17. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
